CO2021001174A2 - Inhibidores de ckd8/19 - Google Patents

Inhibidores de ckd8/19

Info

Publication number
CO2021001174A2
CO2021001174A2 CONC2021/0001174A CO2021001174A CO2021001174A2 CO 2021001174 A2 CO2021001174 A2 CO 2021001174A2 CO 2021001174 A CO2021001174 A CO 2021001174A CO 2021001174 A2 CO2021001174 A2 CO 2021001174A2
Authority
CO
Colombia
Prior art keywords
inhibitors
ckd8
compounds
cdk8
disorders
Prior art date
Application number
CONC2021/0001174A
Other languages
English (en)
Spanish (es)
Inventor
Pavel Andreevich Iakovlev
Aleksei Leonidovich Mindich
Andrei Ivanovich Alafinov
Anton Aleksandrovich Evdokimov
Mariia Andreevna Kasatkina
Elena Aleksandrovna Maksimenko
Mariia Sergeevna Mishina
Anna Jur'evna Chestnova
Aleksei Sergeevich Gavrilov
Liliana Vyacheslavovna Lenshmidt
Sergei Aleksandrovich Silonov
Evgenii Jur'evich Smirnov
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CO2021001174A2 publication Critical patent/CO2021001174A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2021/0001174A 2018-08-03 2021-02-02 Inhibidores de ckd8/19 CO2021001174A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19
PCT/RU2019/050123 WO2020027704A1 (ru) 2018-08-03 2019-07-31 Ингибиторы cdk8/19

Publications (1)

Publication Number Publication Date
CO2021001174A2 true CO2021001174A2 (es) 2021-02-26

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0001174A CO2021001174A2 (es) 2018-08-03 2021-02-02 Inhibidores de ckd8/19

Country Status (19)

Country Link
US (1) US11840531B2 (https=)
EP (1) EP3831829A4 (https=)
JP (1) JP7365396B2 (https=)
KR (1) KR102926889B1 (https=)
CN (1) CN113166140B (https=)
AR (1) AR115898A1 (https=)
AU (1) AU2019313199B2 (https=)
BR (1) BR112021001939A2 (https=)
CA (1) CA3108298A1 (https=)
CL (1) CL2021000282A1 (https=)
CO (1) CO2021001174A2 (https=)
EA (1) EA202190452A1 (https=)
MA (1) MA52375B2 (https=)
MX (1) MX2021001335A (https=)
PE (1) PE20210416A1 (https=)
PH (1) PH12021550258A1 (https=)
RU (1) RU2761824C2 (https=)
TW (1) TWI839374B (https=)
WO (1) WO2020027704A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
MX2010006244A (es) * 2007-12-06 2010-12-02 Schering Corp Moduladores de gamma secretasa.
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-萘啶衍生物
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 新規ナフチリジン及びイソキノリンならびにcdk8/19阻害剤としてのその使用
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
US11213520B2 (en) * 2016-05-23 2022-01-04 Boehringer Ingelheim International Gmbh Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors

Also Published As

Publication number Publication date
TW202012406A (zh) 2020-04-01
AU2019313199A1 (en) 2021-03-11
RU2018128415A (ru) 2020-02-04
PE20210416A1 (es) 2021-03-04
BR112021001939A2 (pt) 2021-04-27
MX2021001335A (es) 2021-04-12
CN113166140B (zh) 2024-06-14
CN113166140A (zh) 2021-07-23
EP3831829A1 (en) 2021-06-09
CL2021000282A1 (es) 2021-08-13
RU2761824C2 (ru) 2021-12-13
JP7365396B2 (ja) 2023-10-19
AR115898A1 (es) 2021-03-10
AU2019313199B2 (en) 2023-07-06
RU2018128415A3 (https=) 2021-03-30
EA202190452A1 (ru) 2021-04-13
US11840531B2 (en) 2023-12-12
MA52375B2 (fr) 2023-02-28
PH12021550258A1 (en) 2021-10-11
WO2020027704A1 (ru) 2020-02-06
TWI839374B (zh) 2024-04-21
MA52375A1 (fr) 2021-12-31
US20210246138A1 (en) 2021-08-12
KR102926889B1 (ko) 2026-02-19
EP3831829A4 (en) 2022-04-20
CA3108298A1 (en) 2020-02-06
KR20210040416A (ko) 2021-04-13
JP2021533143A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CU20110145A7 (es) Derivados de sulfonamida
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2021004566A (es) Compuestos terapeuticos.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CO2021001174A2 (es) Inhibidores de ckd8/19
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CR20150184A (es) Derivados de n-(2-aminacíclica)etil)benzamida como inhibidores de p2x7
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY38133A (es) Nuevos inhibidores de cdk8/19
CL2017001602A1 (es) Derivados de fumagilol.
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
MX2021013771A (es) Compuestos inhibidores del intercambiador de sodio-hidrogeno 3.
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.